Z
Zhe Li
Researcher at Sun Yat-sen University
Publications - 49
Citations - 1232
Zhe Li is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Phosphodiesterase & Virtual screening. The author has an hindex of 16, co-authored 46 publications receiving 866 citations. Previous affiliations of Zhe Li include University of Kentucky.
Papers
More filters
Journal ArticleDOI
Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.
Xiaoyan Liu,Zhe Li,Shuai Liu,Jing Sun,Zhanghua Chen,Min Jiang,Qingling Zhang,Yinghua Wei,Xin Wang,Yi-You Huang,Yinyi Shi,Yanhui Xu,Huifang Xian,Fan Bai,Changxing Ou,Bei Xiong,Andrew M. Lew,Jun Cui,Rongli Fang,Hui Huang,Jincun Zhao,Xuechuan Hong,Yuxia Zhang,Fuling Zhou,Hai-Bin Luo +24 more
TL;DR: An anticoagulation agent dipyridamole (DIP) in silico, which suppressed SARS-CoV-2 replication in vitro, was identified and associated with significantly decreased concentrations of D-dimers, increased lymphocyte and platelet recovery in the circulation, and markedly improved clinical outcomes in comparison to the control patients.
Journal ArticleDOI
Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
Zhe Li,Xin Li,Yi-You Huang,Yaoxing Wu,Runduo Liu,Lingli Zhou,Yuxi Lin,Yuxi Lin,Deyan Wu,Lei Zhang,Hao Liu,Ximing Xu,Kunqian Yu,Yuxia Zhang,Jun Cui,Chang-Guo Zhan,Xin Wang,Hai-Bin Luo +17 more
TL;DR: It has been demonstrated that a new virtual screening approach with accelerated free energy perturbation-based absolute binding free energy (FEP-ABFE) predictions can reach an unprecedentedly high hit rate, leading to successful identification of 15 potent inhibitors of SARS-CoV-2 main protease (Mpro) from 25 computationally selected drugs under a threshold of Ki = 4 μM.
Journal ArticleDOI
Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
TL;DR: The aim of this review is to summarize the outstanding progress that has been made by PDE inhibitors as anti-AD agents with encouraging results in preclinical studies and clinical trials.
Journal ArticleDOI
Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Liping Zhang,Hong Zhang,Yining Zhao,Zhe Li,Shangke Chen,Jing Zhai,Yunyun Chen,Wei Xie,Zhong Wang,Qing Li,Xuehua Zheng,Xiaopeng Hu +11 more
TL;DR: Crystal structures reported here reveal a surprising Trp112 native conformation stabilized by a specific Gln114‐centered hydrogen bond network in the AKR1B10 holoenzyme, and suggest that AKR 1B1 inhibitors could retain their binding affinities toward AKR2B10 by inducing Trp 112 flip to result in an “AKR1 B1‐like” active site in AKR3B10.
Journal ArticleDOI
Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design
Fei Meng,Jing Hou,Yong Xian Shao,Pei Ying Wu,Manna Huang,Xinhai Zhu,Yonghong Cai,Zhe Li,Jie Xu,Peiqing Liu,Hai-Bin Luo,Yiqian Wan,Hengming Ke,Hengming Ke +13 more
TL;DR: The crystal structure of the PDE9 catalytic domain in complex with 28 has been determined and shows a hydrogen bond between 28 and Tyr424, which may account for the 860-fold selectivity of 28 against PDE1B, in comparison with about 30-foldSelectivity of BAY73-6691.